Eden vs Ivim Health

How we scoreOur 1 to 10 brand scores are our own editorial judgment. They are not aggregated from third-party review platforms and they are not the output of a scoring formula.

What a starting price isA starting price is the lowest figure a company lists for a category, not a quote. What you pay follows a clinician's review of your intake, and where a required membership or care plan sits alongside the medication we publish the two charges combined.

Reading a warning letterA close-out letter is FDA's record that it has evaluated a company's corrective actions, so the absence of one means the file is not closed on the public record, and nothing more than that.

Regulatory noticeRegulatory note (verified August 22, 2026): Eden Health International Inc. was sent FDA warning letter MARCS-CMS 728279 on June 8, 2026, following an agency review of tryeden.com in March 2026. The letter lists two findings. The first is the "Eden" name on pictured labels for compounded semaglutide and tirzepatide, which the FDA said represents Eden as the compounder when it is not. The second is the site’s description of its sourcing as "FDA-licensed 503(a) outsourcing facilities," a designation the agency says does not exist, because the FD&C Act creates no FDA approval or license for pharmacies or outsourcing facilities. Both were cited as misbranding under sections 502(a) and 502(bb). FDA has posted no close-out letter, so the matter reads as open. Read the FDA letter

Regulatory noticeRegulatory note (verified August 22, 2026): Ivim Services LLC received FDA warning letter MARCS-CMS 721816 on February 20, 2026, after the agency reviewed ivimhealth.com in December 2025. This letter is narrower than most in the same enforcement round: it quotes no marketing claims at all. The one cited violation concerns labeling. Compounded semaglutide and tirzepatide products pictured on the site show the "Ivim" name, which the FDA said represents Ivim as the compounder when it is not, citing 21 CFR 201.1(h)(2) and the misbranding provisions at FD&C Act 502(a) and 502(bb). We checked FDA’s index for a close-out letter and found none; on the public record the matter remains open. Read the FDA letter

Regulatory noticeRegulatory note (verified October 8, 2026): On February 20, 2026 the FDA issued MEDVi, LLC a warning letter (MARCS-CMS 721455) citing misbranding under sections 502(a) and 502(bb) of the FD&C Act. Reviewing medvi.io in December 2025, the FDA said labels bearing "MEDVi" implied MEDVi compounds the drugs when it does not, and that site copy presenting the compounded drug as having the same active ingredient as Wegovy and Ozempic, and as Mounjaro and Zepbound, implied an FDA approval compounded drugs do not have. The letter adds that introducing or delivering the products it identifies into interstate commerce is a prohibited act under section 301(a), that receiving them in interstate commerce and delivering or offering to deliver them also violates section 301(c), and that a compounded drug product must meet the conditions of section 503A or 503B of the FD&C Act to be exempt from certain requirements, including the new drug approval requirements. When we checked FDA's warning letter index for MEDVi, LLC on October 8, 2026 it showed no response letter and no close-out letter entered against it, so the letter is not closed out on the public record. MEDVi states medvi.io is affiliate-operated rather than company-operated; we could not verify that, and the letter is addressed to MEDVi, LLC. Read the FDA letter